REEP5 and tuberculosis: Regarding the quantitative data in clinical TB patients, the therapy significantly decreased the IFN-γ production in response to TB1- (baseline: 3.2 IU/mL, IQR: 1.2–7.4; end of therapy: 0.2 IU/mL, IQR: 4.6–0.1) and TB2- peptides stimulation (baseline: 4.6 IU/mL, IQR: 1.4–7.8; end of therapy: 0.1 IU/mL, IQR: 0.04–2.9) (p = 0.008 and p = 0.03; respectively) (Fig. 3B).